Friday, December 15, 2017
 
 
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day
TARRYTOWN, N.Y., Dec. 13, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updates related to its collaboration programs with Sanofi, which were highlighted during Sanofi's Sustaining Innovation Analyst Day in Paris, France.
 
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
LONDON, Dec. 12, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.  GSK submitted a suppl.....
 
FDA warns companies for promoting alternatives to street drugs

SILVER SPRING, Md., Dec. 12, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today posted a warning letter to the marketers and distributors of Legal Lean Syrup, a drink, .....

 
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
SILVER SPRING, Md., Dec. 12, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood ve.....
 
iCan:Israel-Cannabis to Bring FDA Approved Nebulizers to the Medical Cannabis Market
TEL AVIV, Israel, Dec. 12, 2017 /PRNewswire/ -- iCAN:Israel-Cannabis and Aura Medical have joined forces to bring FDA approved nebulizers to the burgeoning medical cannabis market.
 



IV Tubing Sets and Accessories Market Value is Expected to Reach US$ 1,248 Million by 2025 - Persistence Market Research
NEW YORK, December 12, 2017 /PRNewswire/ --
 
DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
ATLANTA and RARITAN, N.J., Dec. 12, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical o.....
 
At least 400,000 severely malnourished children at risk of dying in DR Congo's volatile Kasai region

Needs of displaced and returnee families in Kasai remain enormous after nearly two years of conflict and crisis

 
Irene Chatoor, M.D., is recognized by Continental Who's Who
WASHINGTON, Dec. 11, 2017 /PRNewswire/ -- Irene Chatoor, M.D., is recognized by Continental Who's Who as a Pinnacle Professional Member in the field of Mental Health and Psychiatry in recognition of her role as Vice Chair of the Department of Psychiatry for Children's National Health System.  .....
 
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
ATLANTA and RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX®
 
FAU And Max Planck Society Unveil First-Of-Its-Kind Undergraduate Honors Program
BOCA RATON, Fla., Dec. 11, 2017 /PRNewswire-USNewswire/ -- Florida Atlantic University President John Kelly, Max Planck Society President Martin Stratmann, and David Fitzpatrick, CEO of the Max Planck Florida Institute for Neuroscienc.....
 
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
EAST HANOVER, N.J., Dec. 11, 2017 /PRNewswire/ -- Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell pain crisis (SCPC) in patients vs. placebo in key subgroups of adult patient.....
 


 
 
 
 
 
 
 
 
 
 
 
 
 





About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines